CSBR Share Price Performance
US$5.10
-3.20 (-38.55%)
57.5% undervalued intrinsic discount
US$12.00
Fair Value
Price US$5.10
AnalystConsensusTarget US$12.00
Fair ValueUS$12.00
Share Pricen/a
Champions Oncology, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
CSBR Community Narratives
AN
Fair Value
·Fair Value US$12 57.5% undervalued intrinsic discount
Radiopharmaceutical Expansion And AI Data Platforms Will Drive Long Term Oncology Research Demand
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Champions Oncology
57.5% undervalued intrinsic discount
Radiopharmaceutical Expansion And AI Data Platforms Will Drive Long Term Oncology Research Demand
View narrativeAN
Published 12 Dec 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Radiopharmaceutical Expansion And AI Data Platforms Will Drive Long Term Oncology Research Demand
Fair Value: US$12 57.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Champions Oncology, Inc. Key Details
About CSBR
- Founded
- 1985
- Employees
- 214
- CEO
- WebsiteView website
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
